The Incretin Effect in Patients With Gestational Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-04-30

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the reduced incretin effect observed in patients with T2DM in relation to reversibility. The incretin effect will be measured by means of OGTT and iIVGTT in 12 women with GDM during pregnancy (third trimester), and again 2-3 months post partum. It is anticipated that the incretin effect in patients with GDM is reduced - like in patients with other forms of DM. The investigators estimate that approximately 90 % of the patients with GDM re-establish a NGT 2-3 months post partum. This particular group of patients provides a unique possibility for demonstrating the reversibility of the reduced incretin effect in relation to optimal glycaemic control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Real-time Continuous Glucose Monitoring on Severe Complications to Pregnancy in Women With Diabetes

NCT00994357

Diabetes Pregnancy

COMPLETED NA

Pregnancy and Postpartum CGM in GDM

NCT07174245

Gestational Diabetes

RECRUITING

Intrapartum Glucose Management Among Women With Gestational Diabetes Mellitus

NCT02596932

Gestational Diabetes Mellitus

COMPLETED NA

Gestational Diabetes Monitoring and Management

NCT06963528

Gestational Diabetes Pregnancy Complications Pregnancy in Diabetic +16 more

ACTIVE_NOT_RECRUITING

Correlation of CGM Metrics With OGTT and Pregnancy Outcomes in Pregnant Women With or Without a High Risk for GDM

NCT05537480

Pregnancy Complications Diabetes Mellitus Hyperglycemic Disorder

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gestational Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GDM

Patients with Gestational Diabetes Mellitus found during pregnancy by means of 75g OGTT

No interventions assigned to this group

NGT

Pregnant patients with normal glucose tolerance as observed in 75g OGTT

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age above 18 years old
* GDM diagnosed according to WHO guidelines (GDM group) or ruled out by OGTT 75g (Control group)

Exclusion Criteria

* Previous diagnosis of DM
* Positive GAD-65-autoantibodies and/or positive islet cell autoantibodies (ICA)
* Affected biochemical liver parameters (ALAT \> 2 times normal upper range)
* Affected biochemical kidney parameters (se-creatinine \> 130 µM)
* Treatment with medicine interacting with insulin secretion (e.g. steroids)
* Treatment with medicine that can not be paused for 16 hours

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes